← FDA DRUG APPROVALS

FDA ANDA · ANDA206880

LEVETIRACETAM

levetiracetam injection

Sponsor: GLAND

APPLICATION
ANDA206880
TYPE
ANDA
ORIGINAL APPROVAL
2017-10-25
LATEST ACTION
2025-03-26
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

LEVETIRACETAM IN SODIUM CHLORIDEPrescription
LEVETIRACETAM 1.5GM/100ML (15MG/ML) · INJECTABLE · INTRAVENOUS
LEVETIRACETAM IN SODIUM CHLORIDEPrescription
LEVETIRACETAM 500MG/100ML (5MG/ML) · INJECTABLE · INTRAVENOUS
LEVETIRACETAM IN SODIUM CHLORIDEPrescription
LEVETIRACETAM 1GM/100ML (10MG/ML) · INJECTABLE · INTRAVENOUS

Approval history

2025-03-26Labeling · Supplement 8 · standardAP
2023-05-23Labeling · Supplement 7 · standardAP
2020-04-20Labeling · Supplement 5 · standardAP
2020-04-20Labeling · Supplement 4 · standardAP
2017-10-25UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →